Study on the Safety and Tolerability of TP-122 for Treating Ventilator-Associated Pneumonia in Adults

2 1 1

What is this study about?

This clinical trial is focused on studying a condition known as ventilator-associated pneumonia, which is a type of lung infection that can occur in people who are on mechanical ventilators in hospitals. The treatment being tested is called TP-122A, a special mixture of bacteriophages. Bacteriophages are tiny viruses that specifically target and destroy bacteria. In this study, TP-122A is designed to fight against two types of bacteria: Klebsiella pneumoniae and Pseudomonas aeruginosa, which are often responsible for causing ventilator-associated pneumonia.

The purpose of the study is to evaluate the safety and tolerability of TP-122A when given to patients with ventilator-associated pneumonia. Participants in the study will receive multiple doses of TP-122A through inhalation every 8 hours for 7 days. The study will compare the effects of TP-122A combined with standard care to standard care alone. Throughout the study, researchers will monitor participants for any side effects and changes in their health, including vital signs and laboratory tests.

The study aims to understand how well TP-122A is tolerated by patients and whether it can help improve their condition. Researchers will also look at how quickly patients recover from the infection and how long they need to stay on a ventilator or in the intensive care unit. The ultimate goal is to find out if TP-122A can be a safe and effective treatment option for people with ventilator-associated pneumonia.

1 joining the study

Upon joining the study, consent is required. If unable to provide consent personally, a family member or trusted person may do so.

Eligibility includes being 18 years or older and having ventilator-associated pneumonia (VAP) with stable ventilatory requirements.

2 treatment initiation

The treatment involves the administration of a bacteriophage cocktail called TP-122A.

The medication is given through inhalation as a suspension.

3 medication schedule

The TP-122A is administered every 8 hours for a duration of 7 days.

This is in addition to the standard care (SoC) provided for VAP.

4 monitoring and assessments

Throughout the trial, various assessments are conducted to monitor safety and tolerability.

These include checking for adverse events, changes in clinical laboratory parameters, vital signs, and electrocardiogram (ECG) results.

5 follow-up

After the treatment period, follow-up assessments are conducted to evaluate the outcomes.

These assessments include checking for clinical cure, microbiological response, and overall survival.

Who Can Join the Study?

Subjects must be able and willing to sign the informed consent form. If the subject cannot do so, a family member or trusted person can provide consent.
Subjects must be 18 years old or older.
Subjects must have Ventilator-Associated Pneumonia (VAP) with stable breathing support needs. This includes specific measures of oxygen levels and breathing support settings.
Subjects must show at least one of the following: low oxygen levels, need for changes in breathing support to improve oxygen, or new respiratory secretions.
Subjects must show at least one of the following signs: fever, low body temperature, high or low white blood cell count, or a high percentage of immature white blood cells.
Subjects must have a confirmed infection with P. aeruginosa in the lower respiratory tract, diagnosed through specific tests.
Female subjects who can have children must have a negative pregnancy test at the start of the study.
Subjects must be registered in a social security scheme.

Who Cannot Join the Study?

Patients who are not adults cannot participate. This means only individuals who are 18 years or older are eligible.
Patients who are part of a vulnerable population are not allowed to join. A vulnerable population includes groups like pregnant women, prisoners, or those unable to give consent.
Patients who have medical conditions other than Ventilator-Associated Pneumonia may not be eligible. Ventilator-Associated Pneumonia is a lung infection that occurs in people who are on a ventilator, a machine that helps them breathe.
Patients who cannot follow the study procedures, such as taking the medication every 8 hours for 7 days, may be excluded.
Patients who have allergies or reactions to the study medication or its ingredients may not be able to participate.
Patients who are currently participating in another clinical trial may not be eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Centre Hospitalier Universitaire De Nantes	Nantes	France
Chrugo Hcsdfaylzks Ez Utmqedkaajmwa Dt Lvgyeiq	Limoges	France

Trial status

Country	Status	Recruitment Start
France	Not yet recruiting	01.04.2024

Trial locations

Investigated drugs:

TP-122A is a bacteriophage cocktail being studied for its potential to treat ventilator-associated pneumonia. Bacteriophages are viruses that specifically target and destroy bacteria. In this trial, TP-122A is administered through nebulization, which means it is inhaled as a mist, allowing it to reach the lungs directly. The study aims to assess the safety and tolerability of this treatment when given multiple times a day over a week.

Standard of Care (SoC) refers to the usual treatment provided to patients with ventilator-associated pneumonia. This can include antibiotics and other supportive measures to help manage the infection and support the patient’s breathing. In this trial, TP-122A is given in addition to the standard of care to see if it offers any additional benefits.

Ventilator-Associated Pneumonia – This is a type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals. It typically develops 48 hours or more after mechanical ventilation is initiated. The disease is caused by bacteria that enter the lungs through the ventilator tube. Symptoms may include fever, increased white blood cell count, and purulent sputum. The progression of the disease can lead to worsening respiratory function and increased oxygen requirements. It is a common complication in intensive care units and requires careful monitoring.

Trial ID:

2023-508825-29-00

Trial Phase:

Phase I and Phase II (Integrated) – First administration to humans

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Safety and Tolerability of TP-122 for Treating Ventilator-Associated Pneumonia in Adults

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?